Jaundice resident survival guide: Difference between revisions
No edit summary |
|||
(24 intermediate revisions by 3 users not shown) | |||
Line 24: | Line 24: | ||
{{SK}} Approach to jaundice, Jaundice workup, Jaundice management | {{SK}} Approach to jaundice, Jaundice workup, Jaundice management | ||
==Overview== | ==Overview== | ||
The classic definition of [[jaundice]] is a | The classic definition of [[jaundice]] is a [[serum bilirubin]] level higher than 2.5 to 3 mg per dL (42.8 to 51.3 μper L) in conjunction with [[clinical]] evidence of [[yellow skin]] and [[sclera]]. The causes of [[jaundice]] can be classified by measuring total [[bilirubin]]. The [[Conjugated bilirubin|conjugated]] and [[Unconjugated bilirubin|unconjugated]] levels determine whether there is [[dysfunction]] of [[bilirubin metabolism]]. | ||
==Causes== | ==Causes== | ||
Line 40: | Line 40: | ||
*[[Alcoholic hepatitis]] | *[[Alcoholic hepatitis]] | ||
*[[Viral hepatitis]] | *[[Viral hepatitis]] | ||
*Obstructive Jaundice due to [[choledocholithiasis]] or [[malignancy]] | *[[Obstructive Jaundice]] due to [[choledocholithiasis]] or [[malignancy]] | ||
*Decompensated [[chronic liver disease]] | *Decompensated [[chronic liver disease]] | ||
Line 49: | Line 49: | ||
==Diagnosis== | ==Diagnosis== | ||
Shown below is an algorithm summarizing the [[diagnosis]] of jaundice.<ref name="pmid15684121">{{cite journal |vauthors=Giannini EG, Testa R, Savarino V |title=Liver enzyme alteration: a guide for clinicians |journal=CMAJ |volume=172 |issue=3 |pages=367–79 |date=February 2005 |pmid=15684121 |pmc=545762 |doi=10.1503/cmaj.1040752 |url=}}</ref><ref name="pmid21250253">{{cite journal |vauthors=Walker HK, Hall WD, Hurst JW, Stillman AE |title= |journal= |volume= |issue= |pages= |date= |pmid=21250253 |doi= |url=}}</ref><ref name="pmid27904243">{{cite journal |vauthors=Gondal B, Aronsohn A |title=A Systematic Approach to Patients with Jaundice |journal=Semin Intervent Radiol |volume=33 |issue=4 |pages=253–258 |date=December 2016 |pmid=27904243 |pmc=5088098 |doi=10.1055/s-0036-1592331 |url=}}</ref><ref name="pmid20378138">{{cite journal |vauthors=Syhavong B, Rasachack B, Smythe L, Rolain JM, Roque-Afonso AM, Jenjaroen K, Soukkhaserm V, Phongmany S, Phetsouvanh R, Soukkhaserm S, Thammavong T, Mayxay M, Blacksell SD, Barnes E, Parola P, Dussaix E, Raoult D, Humphreys I, Klenerman P, White NJ, Newton PN |title=The infective causes of hepatitis and jaundice amongst hospitalised patients in Vientiane, Laos |journal=Trans. R. Soc. Trop. Med. Hyg. |volume=104 |issue=7 |pages=475–83 |date=July 2010 |pmid=20378138 |pmc=2896487 |doi=10.1016/j.trstmh.2010.03.002 |url=}}</ref> | Shown below is an algorithm summarizing the [[diagnosis]] of jaundice.<ref name="pmid15684121">{{cite journal |vauthors=Giannini EG, Testa R, Savarino V |title=Liver enzyme alteration: a guide for clinicians |journal=CMAJ |volume=172 |issue=3 |pages=367–79 |date=February 2005 |pmid=15684121 |pmc=545762 |doi=10.1503/cmaj.1040752 |url=}}</ref><ref name="pmid21250253">{{cite journal |vauthors=Walker HK, Hall WD, Hurst JW, Stillman AE |title= |journal= |volume= |issue= |pages= |date= |pmid=21250253 |doi= |url=}}</ref><ref name="pmid27904243">{{cite journal |vauthors=Gondal B, Aronsohn A |title=A Systematic Approach to Patients with Jaundice |journal=Semin Intervent Radiol |volume=33 |issue=4 |pages=253–258 |date=December 2016 |pmid=27904243 |pmc=5088098 |doi=10.1055/s-0036-1592331 |url=}}</ref><ref name="pmid20378138">{{cite journal |vauthors=Syhavong B, Rasachack B, Smythe L, Rolain JM, Roque-Afonso AM, Jenjaroen K, Soukkhaserm V, Phongmany S, Phetsouvanh R, Soukkhaserm S, Thammavong T, Mayxay M, Blacksell SD, Barnes E, Parola P, Dussaix E, Raoult D, Humphreys I, Klenerman P, White NJ, Newton PN |title=The infective causes of hepatitis and jaundice amongst hospitalised patients in Vientiane, Laos |journal=Trans. R. Soc. Trop. Med. Hyg. |volume=104 |issue=7 |pages=475–83 |date=July 2010 |pmid=20378138 |pmc=2896487 |doi=10.1016/j.trstmh.2010.03.002 |url=}}</ref><br> | ||
'''Abbreviations''': | '''Abbreviations''': [[ALT]]:[[Alanine transaminase]], [[AST]]:[[Aspartate transaminase]], [[ALP]]: [[Alkaline phosphatase]], [[INR]]:[[International normalized ratio]], [[ERCP]]:Endoscopic retrograde cholangiopancreatography, [[HAV:]] [[Hepatitis A virus]], [[HBV]]: [[Hepatitis B virus]], [[HCV]]: [[Hepatitis C virus]], [[TIBC]]:[[Total iron binding capacity]],[[Hb]]: [[Hemoglobin]], [[LDH]]: [[lactate dehydrogenase]], [[HbA1C]]:[[Hemoglobin A1c]], [[CBC]]:[[Complete blood count]], [[LFT]]: [[Liver function tests]], [[MRCP]]: [[Magnetic resonance cholangiopancreatography]], [[G6PD]]:[[Glucose-6-phosphate dehydrogenase deficiency]] | ||
{{familytree/start |summary=PE diagnosis Algorithm.}} | {{familytree/start |summary=PE diagnosis Algorithm.}} | ||
{{familytree | | | | | | | | | | | A01 | | | | | | | | | | |A01=<div style="float: left; text-align: left;width: 20em; padding:1em;">'''Characterize the jaundice duration and frequency<br>''' ❑Duration: short vs long <br>❑Frequency: episodic vesus constant</div>}} | {{familytree | | | | | | | | | | | A01 | | | | | | | | | | |A01=<div style="float: left; text-align: left;width: 20em; padding:1em;">'''Characterize the jaundice duration and frequency<br>''' ❑Duration: short vs long <br>❑Frequency: episodic vesus constant</div>}} | ||
Line 72: | Line 72: | ||
❑ [[Parentral]] exposure<br> | ❑ [[Parentral]] exposure<br> | ||
:❑ [[Blood transfusion]]<br> | :❑ [[Blood transfusion]]<br> | ||
:❑ IV drug abuse<br> | :❑ [[IV drug abusers|IV drug abuse]]<br> | ||
❑ Recent travel history <br> | ❑ Recent travel history <br> | ||
❑ Social history | ❑ Social history | ||
Line 85: | Line 85: | ||
'''[[Skin]] exam'''<br> ❑ Check for:<br> | '''[[Skin]] exam'''<br> ❑ Check for:<br> | ||
:❑ Scratch marks<br> | :❑ Scratch marks<br> | ||
:❑ [[Melanin]] pigmentation<br> | :❑ [[Melanin]] [[pigmentation]]<br> | ||
:❑ [[Xanthoma]] of [[eyelids]] (chronic [[cholestasis]])<br> | :❑ [[Xanthoma]] of [[eyelids]] (chronic [[cholestasis]])<br> | ||
:❑ [[Signs]] of [[liver disease]]: [[spider nevi]], [[palmar]] [[erythema]]<br> | :❑ [[Signs]] of [[liver disease]]: [[spider nevi]], [[palmar]] [[erythema]]<br> | ||
Line 102: | Line 102: | ||
❑ Check [[gallbladder]] area if it is tender<br> | ❑ Check [[gallbladder]] area if it is tender<br> | ||
:❑ Positive [[murphy sign]] due to [[choledocholithiasis]]<br> | :❑ Positive [[murphy sign]] due to [[choledocholithiasis]]<br> | ||
:❑ Palpable, visibly enlarged [[gallbladder]] can be due to [[pancreatic cancer]]<br> | :❑ [[Palpable]], visibly enlarged [[gallbladder]] can be due to [[pancreatic cancer]]<br> | ||
❑ [[Splenomegaly]] can be seen in [[hemolytic]] states, [[Hodgkin’s lymphoma]], [[portal hypertension]]<br> | ❑ [[Splenomegaly]] can be seen in [[hemolytic]] states, [[Hodgkin’s lymphoma]], [[portal hypertension]]<br> | ||
❑ [[Ascites]] due to [[cirrhosis]]/[[abdominal]] [[malignancy]]<br>caput medosa<br> | ❑ [[Ascites]] due to [[cirrhosis]]/[[abdominal]] [[malignancy]]<br>caput medosa<br> | ||
Line 163: | Line 163: | ||
| | | | ||
*Work-up and detect the [[cause]] of [[hemolysis]], if low [[Hb]], high [[LDH]], Low [[haptoglobin]], and [[reticulocytes]] present.<br> | *Work-up and detect the [[cause]] of [[hemolysis]], if low [[Hb]], high [[LDH]], Low [[haptoglobin]], and [[reticulocytes]] present.<br> | ||
*[[G6PD]] deficiency - | *[[G6PD]] deficiency - the majority recover on their own, if progress to [[hemolytic anemia]], [[oxygen]] therapy, or [[blood transfusion]] may be required. Avoid precipitants and etiological factors <br> | ||
*[[Spherocytosis]]- | *[[Spherocytosis]][-[phototherapy]] and/or exchange [[transfusion]] for [[infants]], [[folic acid]] for maintaining [[erythropoiesis]]. | ||
*[[Sickle cell anemia]]- reduce pain and prevent complications, blood transfusions and supplemental oxygen, as well as a bone marrow transplant.<br> | **[[Splenectomy]] is the definitive treatment <br> | ||
*Immune-related [[hemolysis]] – [[corticosteroids]], [[folic acid]] is the | *[[Sickle cell anemia]]- reduce pain and prevent [[complications]], [[blood transfusions]] and supplemental [[oxygen]], as well as a [[bone marrow transplant]].<br> | ||
*Parasitic Infections like [[malaria]] are treated with [[antimalarial]] drugs like [[chloroquine]], [[artesunate]], [[lumefantrine]],[[amodiaquine]] <br> | *Immune-related [[hemolysis]] – [[corticosteroids]], [[folic acid]] is the first line of treatment<br> | ||
*Ineffective erythropoiesis- iron and folic acid & B12 supplementation, repeated blood transfusions | *[[Parasitic]] Infections like [[malaria]] are treated with [[antimalarial]] drugs like [[chloroquine]], [[artesunate]], [[lumefantrine]],[[amodiaquine]] <br> | ||
*Ineffective erythropoiesis- [[iron]] and [[folic acid]] & vitamin B12 supplementation, repeated [[blood transfusions]]. | |||
|- | |- | ||
|'''Managment of isolated unconjugated jaundice, Non-hemolytic'''|| | |'''Managment of isolated unconjugated jaundice, Non-hemolytic'''|| | ||
*[[ Gilbert's syndrome]] does not produce symptoms or adverse effects and patients have a normal life span<br> | *[[ Gilbert's syndrome]] does not produce [[symptoms]] or adverse effects and [[patients]] have a normal life span<br> | ||
*[[Crigler-Najjar]] type I is fatal in early life due to development of [[kernicterus]].<br> | *[[Crigler-Najjar]] type I is fatal in early life due to development of [[kernicterus]].<br> | ||
*[[Crigler-Najjar]] type II is compatible with a normal life.| | *[[Crigler-Najjar]] type II is compatible with a normal life.| | ||
| | | | ||
*Phenobarbital can decrease serum bilirubin by enzymatic induction of UDPGT(Uridine [[Glucuronosyltransferase]]) in Crigler-Najjar type II. | *[[Phenobarbital]] can decrease serum [[bilirubin]] by enzymatic induction of UDPGT (Uridine [[Glucuronosyltransferase]]) in Crigler-Najjar type II. | ||
|- | |- | ||
|'''Managment of isolated conjugated jaundice'''|| | |'''Managment of isolated conjugated jaundice'''|| | ||
*[[Dubin-Johnson syndrome]]- doesn't produce any symptoms and compatible with a normal life span.<br> | *[[Dubin-Johnson syndrome]]- doesn't produce any [[symptoms]] and compatible with a normal life span.<br> | ||
*[[Rotor's syndrome]] is a harmless chronic hyperbilirubinemia | | *[[Rotor's syndrome]] is a harmless chronic hyperbilirubinemia | | ||
| | | | ||
*Suspect for Dubin-Johnson syndrome before considering surgery if the healthy patient with long-standing [[conjugated]] [[hyperbilirubinemia]], other normal liver function tests, and a non visualized gallbladder.<br> | *Suspect for Dubin-Johnson syndrome before considering surgery if the healthy [[patient]] with long-standing [[conjugated]] [[hyperbilirubinemia]], other normal [[liver]] function tests, and a non visualized [[gallbladder]].<br> | ||
*Hepatic architecture is normal but there is an accumulation of hepatic pigment compatible with [[melanin]] in patients with Dubin-Johnson syndrome<br> | *Hepatic architecture is normal but there is an accumulation of [[hepatic]] pigment compatible with [[melanin]] in patients with Dubin-Johnson syndrome<br> | ||
*In Rotor's syndrome the [[gallbladder]] opacifies normally with cholecystographic dye and no pigmentation be seen in the liver. | *In Rotor's syndrome the [[gallbladder]] opacifies normally with cholecystographic dye and no pigmentation be seen in the [[liver]]. | ||
|- | |- | ||
|'''Managment of conjugated & unconjugated hyperbilirubinemia jaundice with ⇈[[AST]]/[[ALT]] out of proportion to [[ALP]]''''|| | |'''Managment of conjugated & unconjugated hyperbilirubinemia jaundice with ⇈[[AST]]/[[ALT]] out of proportion to [[ALP]]''''|| | ||
Line 189: | Line 190: | ||
*Social history: [[alcohol]], sexual history<br> | *Social history: [[alcohol]], sexual history<br> | ||
*Family history of [[Wilson's disease]] or [[hemochromatosis]]<br> | *Family history of [[Wilson's disease]] or [[hemochromatosis]]<br> | ||
*Review medications<br> | *Review [[medications]]<br> | ||
*Pregnancy test<BR>[[HELLP syndrome]], [[AFLP]]<BR> | *Pregnancy test<BR>[[HELLP syndrome]], [[AFLP]]<BR> | ||
*Toxicology screen<br>Acetaminophen level<br> | *Toxicology screen<br>[[Acetaminophen level]]<br> | ||
*Mild elevation in aminotransferase levels in female patients with concomitant [[autoimmune]] disorders (e.g., [[autoimmune thyroiditis]], connective tissue diseases) is suggestive of autoimmune hepatitis.<br> | *Mild elevation in [[aminotransferase]] levels in female [[patients]] with concomitant [[autoimmune]] disorders (e.g., [[autoimmune thyroiditis]], connective tissue diseases) is suggestive of autoimmune hepatitis.<br> | ||
*Consider work-up for rare cases<br>Liver biopsy if results negative<br> | *Consider work-up for rare cases<br>Liver biopsy if results negative<br> | ||
*Ischemic acute liver damage is more likely in patients with concomitant clinical conditions such as sepsis or low-flow hemodynamic state or right-sided heart failure| | *Ischemic acute liver damage is more likely in patients with concomitant clinical conditions such as sepsis or low-flow hemodynamic state or right-sided heart failure| | ||
Line 233: | Line 234: | ||
*'''[[Alcohol]] Use''': screen for [[Alcohol abuse|alcohol use disorders]] in all [[patients]]. | *'''[[Alcohol]] Use''': screen for [[Alcohol abuse|alcohol use disorders]] in all [[patients]]. | ||
*'''[[Medications]]''': discuss the safety of limited (2 gram/day) acetaminophen use, review pharmacologic history, and discontinue [[medications]] that cause [[hemolysis]] or drug-induced [[hepatitis]]. | *'''[[Medications]]''': discuss the safety of limited (2 gram/day) acetaminophen use, review pharmacologic history, and discontinue [[medications]] that cause [[hemolysis]] or drug-induced [[hepatitis]]. | ||
*Treat | *Treat underlying disease [[conditions]]. | ||
*[[Liver Transplant]] Referral: refer early when a [[patient]] | *[[Liver Transplant]] Referral: refer early when a [[patient]] requires liver transplant. | ||
*Palliative Care: address goals of care and refer to palliative care early especially for [[patients]] with [[tumors]]. | *[[Palliative Care]]: address goals of care and refer to palliative care early especially for [[patients]] with [[tumors]]. | ||
==Don'ts== | ==Don'ts== | ||
Line 245: | Line 246: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Primary care]] | |||
[[Category:Up-To-Date]] |
Latest revision as of 14:54, 14 October 2020
Jaundice Resident Survival Guide |
---|
Overview |
Causes |
Diagnosis |
Treatment |
Do's |
Don'ts |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Roghayeh Marandi, M.D.[2]
Synonyms and keywords: Approach to jaundice, Jaundice workup, Jaundice management
Overview
The classic definition of jaundice is a serum bilirubin level higher than 2.5 to 3 mg per dL (42.8 to 51.3 μper L) in conjunction with clinical evidence of yellow skin and sclera. The causes of jaundice can be classified by measuring total bilirubin. The conjugated and unconjugated levels determine whether there is dysfunction of bilirubin metabolism.
Causes
Life Threatening Causes
Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated.
- Ascending cholangitis
- Sepsis
- Acute liver failure (the combination of jaundice with hepatic encephalopathy)
Common Causes
Common causes of acute Jaundice[1]
- Gilbert syndrome
- Alcoholic hepatitis
- Viral hepatitis
- Obstructive Jaundice due to choledocholithiasis or malignancy
- Decompensated chronic liver disease
Common causes of chronic progressive jaundice
Diagnosis
Shown below is an algorithm summarizing the diagnosis of jaundice.[2][3][4][5]
Abbreviations: ALT:Alanine transaminase, AST:Aspartate transaminase, ALP: Alkaline phosphatase, INR:International normalized ratio, ERCP:Endoscopic retrograde cholangiopancreatography, HAV: Hepatitis A virus, HBV: Hepatitis B virus, HCV: Hepatitis C virus, TIBC:Total iron binding capacity,Hb: Hemoglobin, LDH: lactate dehydrogenase, HbA1C:Hemoglobin A1c, CBC:Complete blood count, LFT: Liver function tests, MRCP: Magnetic resonance cholangiopancreatography, G6PD:Glucose-6-phosphate dehydrogenase deficiency
Characterize the jaundice duration and frequency ❑Duration: short vs long ❑Frequency: episodic vesus constant | |||||||||||||||||||||||||||||||||||||||||||||||
Ask about associated symptoms ❑ Abdominal pain (episodic or constant) ❑ Abdominal distension ❑ Fever ❑ Clay colored stool ❑ Dark urine ❑ Weight gain or loss ❑ Anorexia ❑ Dyspepsia ❑ Arthralgia ❑ Myalgia ❑ Back pain ❑ Rash ❑ Confusion | |||||||||||||||||||||||||||||||||||||||||||||||
Inquire about ❑ Past medical history ❑ Blood disorder
❑ Family history of ❑ Medication history ❑ Recent travel history
| |||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient General Appearance ❑ Check for:
Skin exam
Cardiac exam
❑ Check gallbladder area if it is tender
❑ Splenomegaly can be seen in hemolytic states, Hodgkin’s lymphoma, portal hypertension
| |||||||||||||||||||||||||||||||||||||||||||||||
Order ❑ Blood tests
❑ Urine
| |||||||||||||||||||||||||||||||||||||||||||||||
Isolated unconjugated hyperbilirubinemia] | Isolated conjugated hyperbilirubinemia | Unconjugated & conjugated hyperbilirubinemia | |||||||||||||||||||||||||||||||||||||||||||||
❑ Inquire about any recent trauma hematoma blood transfusion | ❑ Dubin-Johnson syndrome ❑ Rotor syndrome | ||||||||||||||||||||||||||||||||||||||||||||||
If none of them | With Liver enzyme changes | with ↑ INR,↓ Albumin,↓ Platelet | |||||||||||||||||||||||||||||||||||||||||||||
❑ Check Hb,LDH,Haptoglobin,Recticulocyte count | If ⇈AST/ALT out of proportion to ALP | If ⇈AlP out of proportion to AST/ALT | Suggestive of cCirrhosis Additional tests to find the cause of cirrhosis Hepatitis serology Iron panel Abdominal Ultrasound Workup for Automimmune hepatitis, NAFLD, Hemochromatosis & other causes of cirrhosis | ||||||||||||||||||||||||||||||||||||||||||||
Abnormal | Normal | Hepatocellular pattern | Cholestatic pattern | ||||||||||||||||||||||||||||||||||||||||||||
Start workup of hemolytic anemia with blood smear & coombs test | ❑ Gilbert syndrome ❑ Crigler-Najjar type I,II | Additional work-up for specific diseases Viral hepatitis serology(e.g. HAV,HBV,HCV) Toxicology screen Acetaminophen level Cereuloplasmin if patient<40 years of age Autoantibodies (ANA,Anti-sm,LKM,...) Ferritin & TIBC HbA1c Pregnancy test a1-antitrypsin ❑Consider work-up for rare cases Liver biopsy if results negative | Ultrasound | ||||||||||||||||||||||||||||||||||||||||||||
Consider following based on the results: ❑ Sickle cell disease ❑ Hereditary spherocytosis ❑ G6PD deficiency ❑ Medications effect (Rifampicin, Probencid) ❑ Immune-mediated hemolysis | Consider following based on the results: ❑ Viral hepatitis ❑ NAFLD (Non-alcoholic liver disease) ❑ ppAlcoholic liver disease]] ❑ Metabolic/genetic diseases Hereditary hemochromatosis Wilson's disease Alpha-1 antitrypsin deficiency ❑ Drug-induced and supplemental-induced injury Acetaminophen, kavakava, Vinyl cholride ❑ Pregnancy AFLP,HELLP syndrome ❑ Autoimmune hepatitis ❑ Ischemic hepatitis | Bile ducts dilated | Bile ducts not dilated | ||||||||||||||||||||||||||||||||||||||||||||
ERCP/CT | Additional work-up for intrahepatic cholestasis | ||||||||||||||||||||||||||||||||||||||||||||||
❑ Common bile duct stones ❑ Biliray stricture ❑ Worms/flukes ❑ Extrahepatic sources: ❑ Cholangiocarcinoma ❑ Pancreatic cancer | Consider following based on the results: | ||||||||||||||||||||||||||||||||||||||||||||||
Treatment
Type of hyperbilirubinemia | Diagnostic Indicators | Management Recommendations |
---|---|---|
Managment of isolated unconjugated jaundice, hemolytic |
|
|
Managment of isolated unconjugated jaundice, Non-hemolytic |
|
|
Managment of isolated conjugated jaundice |
|
|
Managment of conjugated & unconjugated hyperbilirubinemia jaundice with ⇈AST/ALT out of proportion to ALP' |
|
|
Managment of conjugated & unconjugated hyperbilirubinemia jaundice with ⇈ AlP out of proportion to AST/ALT |
|
|
Managment of conjugated & unconjugated hyperbilirubinemia jaundice with ↑ INR,↓ Alb,↓ PLT | |
|
Do's
- Alcohol Use: screen for alcohol use disorders in all patients.
- Medications: discuss the safety of limited (2 gram/day) acetaminophen use, review pharmacologic history, and discontinue medications that cause hemolysis or drug-induced hepatitis.
- Treat underlying disease conditions.
- Liver Transplant Referral: refer early when a patient requires liver transplant.
- Palliative Care: address goals of care and refer to palliative care early especially for patients with tumors.
Don'ts
- Forget to discuss medication to avoid, especially in patients with G6PD or drug-induced hepatitis.
- Delay palliative care until the patient is in a critical state.
- Delay referring a patient to the liver transplant center until the patient is hospitalized in life-threatening condition.
References
- ↑ Warner, Ben; Wilkinson, Mark (2017). "Acute jaundice": 150–154. doi:10.1002/9781119389613.ch23.
- ↑ Giannini EG, Testa R, Savarino V (February 2005). "Liver enzyme alteration: a guide for clinicians". CMAJ. 172 (3): 367–79. doi:10.1503/cmaj.1040752. PMC 545762. PMID 15684121.
- ↑ 3.0 3.1 Walker HK, Hall WD, Hurst JW, Stillman AE. PMID 21250253. Missing or empty
|title=
(help) - ↑ Gondal B, Aronsohn A (December 2016). "A Systematic Approach to Patients with Jaundice". Semin Intervent Radiol. 33 (4): 253–258. doi:10.1055/s-0036-1592331. PMC 5088098. PMID 27904243.
- ↑ Syhavong B, Rasachack B, Smythe L, Rolain JM, Roque-Afonso AM, Jenjaroen K, Soukkhaserm V, Phongmany S, Phetsouvanh R, Soukkhaserm S, Thammavong T, Mayxay M, Blacksell SD, Barnes E, Parola P, Dussaix E, Raoult D, Humphreys I, Klenerman P, White NJ, Newton PN (July 2010). "The infective causes of hepatitis and jaundice amongst hospitalised patients in Vientiane, Laos". Trans. R. Soc. Trop. Med. Hyg. 104 (7): 475–83. doi:10.1016/j.trstmh.2010.03.002. PMC 2896487. PMID 20378138.
- ↑ Shroff H, Maddur H (April 2020). "Isolated Elevated Bilirubin". Clin Liver Dis (Hoboken). 15 (4): 153–156. doi:10.1002/cld.944. PMC 7206321 Check
|pmc=
value (help). PMID 32395242 Check|pmid=
value (help). - ↑ Garcia-Tsao G (February 2001). "Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis". Gastroenterology. 120 (3): 726–48. doi:10.1053/gast.2001.22580. PMID 11179247.
- ↑ McCullough AJ, O'Connor JF (November 1998). "Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology". Am. J. Gastroenterol. 93 (11): 2022–36. doi:10.1111/j.1572-0241.1998.00587.x. PMID 9820369.
- ↑ Baldwin C, Olarewaju O. PMID 32644330 Check
|pmid=
value (help). Missing or empty|title=
(help)